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Background: Tomato-based food products have health-promoting and disease-preventing effects. Some tomato
juice ingredients may have health benefits for middle-aged women, including women with menopausal symptoms
and cardiovascular diseases. We investigated the net effect of tomato juice intake on several health parameters in
women in this age group.
Methods: An open-label, single-arm study was conducted, involving 95 women (40-60-years-old) who had at least
one menopausal symptom. The participants refrained from foods and drinks rich in tomato and tomato-based
products for 2 weeks prior to the study and during the 8 weeks of tomato juice consumption. After the run-in
period, the women were asked to consume 200 mL of unsalted tomato juice, twice daily for 8 weeks. Their menopausal
symptoms were evaluated using the Menopausal Symptom Scale (MSS), Hospital Anxiety and Depression Scale (HADS),
and Athens Insomnia Scale (AIS) before the study, and at 4 and 8 weeks after study commencement. At the same times,
body composition; blood pressure; heart rate; resting energy expenditures (REEs); and serum levels of triglyceride (TG),
cholesterol, glucose, and hemoglobin A1c were measured.
Results: Ninety-three women (98%) completed the study. The following parameters showed significant changes,
compared with baseline, at study weeks 4 and 8 (mean ± standard deviation at baseline, week 4, and week 8): (1) the MSS
score improved (9.9 ± 5.2, 8.5 ± 5.0, 8.3 ± 5.0; P < 0.0001, repeated measures analysis of variance(ANOVA)), (2) the HADS-
anxiety subscale score improved (5.3 ± 2.7, 4.8 ± 2.4, 4.9 ± 2.9; P = 0.041, Friedman test), (3) heart rate increased
(62.6 ± 9.4 bpm, 64.4 ± 8.6 bpm, 63.8 ± 8.2 bpm; P = 0.028, Friedman test), (4) REE increased (1980 ± 368 kcal/day, 2108 ±
440 kcal/day, 2149 ± 470 kcal/day; P = 0.0030, repeated measures ANOVA), (5) serum TG level decreased in the subgroup
of women (n = 22) who had high TG (150 mg/dL or higher) at baseline (237.8 ± 88.9 mg/dL, 166.7 ± 86.1 mg/dL, 170.9 ±
109.7 mg/dL; P = 0.0002, Friedman test).
Conclusions: Tomato juice intake alleviated menopausal symptoms, including anxiety, increased REEs and heart rate, and
lowered high baseline serum TG levels in middle-aged women.
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used in the current study
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Middle-aged women are not only bothered by the phys-
ical and psychological symptoms of menopause, but are
also at increased risk for cardiovascular diseases (CVDs),
such as central obesity, hypertension, dyslipidemia, and
diabetes [1-4], which are partly induced as a result of
diminished estrogen production [5]. CVD is the number
one cause of death worldwide, accounting for 17.3 mil-
lion (30%) deaths, globally, in 2008 [6]. Most CVDs
could be theoretically prevented through an elimination
of risk factors, such as tobacco use, unhealthy diets,
obesity, high blood pressure, impaired glucose tolerance,
and raised lipids [7]; however, modification of one’s own
lifestyle is often difficult.
Tomato juice contains a variety of bioactive ingredi-
ents, such as gamma-aminobutyric acid (GABA), lyco-
pene, 13-oxo-9,11-octadecadienoic acid (13-oxo-ODA),
and esculeoside A, which may provide physical and psy-
chological health benefits for middle-aged women. For
example, GABA reduces psychological stress [8] and
lowers blood pressure [9]. Lycopene has been reported
to have anti-cancer effects and anti-oxidative effects, and
to be effective at mitigating cardiovascular diseases,
osteoporosis, and mental disorders [10-14]. Recently,
13-oxo-ODA was shown to lower plasma and hepatic
triglyceride (TG) levels in an animal model of obesity
[15]. Esculeoside A, a tomato saponin, was also shown
to reduce serum levels of TG and cholesterol, and to
ameliorate atherosclerotic lesions in ApoE-deficient mice
[16]. Compared to fresh tomatoes, tomato juice has sev-
eral advantages, including an increased level of extract-
able lycopene [17], and elevated antioxidant capacity (as
a result of activation through the canning (heating)
process) [18], and additionally, 13-oxo-ODA is found
only in tomato juice [15]. Moreover, a recent research
showed that tomato vinegar beverage improved glucose
tolerance in high-fat diet-induced obese mice [19].
In the present study, we investigated the net effect of
tomato juice intake on a variety of health parameters in
middle-aged women, based on the hypothesis that anti-
oxidative effect of lycopene and relaxing effect of GABA
may alleviate physical and psychological symptoms of
menopause; 13-oxo-ODA and Esculeoside A may in-
crease resting energy expenditure (REE) and lower the
serum level of triglyceride.
Methods
We conducted an open-label, single-arm study at the
Menopause Clinic of the Tokyo Medical and Dental
University. The study protocol was reviewed and ap-
proved by the Tokyo Medical and Dental University Re-
view Board, and written informed consent was obtained
from all participants. The study was conducted in ac-
cordance with the Declaration of Helsinki [20].Ninety-five Japanese women participated in this study.
The inclusion criteria were as follows: ages between 40
and 60; having at least one menopausal symptom on the
Menopausal symptom scale (MSS) (score >1). The exclu-
sion criteria were as follows: medication for hypertension,
dyslipidemia, diabetes, or other cardiovascular diseases;
intake of vitamins, lycopene, GABA or other supplements
that could affect the parameters to be evaluated; allergy to
tomato or tomato products. The participants were re-
cruited through advertisements posted in our hospital and
in the patients’ social network. The participants were clas-
sified as follows: premenopausal (regular menstrual cycles
in the past 3 months), perimenopausal (a menstrual
period within the past 12 months but a missed period or
irregular cycles in the past 3 months), postmenopausal
(no menstrual period in the past 12 months), or had surgi-
cally or medically induced menopause (hysterectomy or
chemotherapy for breast cancer).
From 2 weeks before the start until study termination,
the participants refrained from foods and drinks rich in
tomatoes and tomato products. After the run-in period,
each participant was asked to consume 200 mL of un-
salted tomato juice (Nippon Del Monte, Gunma, Japan)
twice daily, just before breakfast and dinner, for 8 weeks.
The nutritional composition of the tomato juice used in
the current study is shown in Table 1. The product was
manufactured in compliance with the Food Safety System
Certification (FSSC) 22000 adopted by the Global Food
Safety Initiative (GFSI). Adherence to the study protocol
was confirmed by checking the participants’ diaries in-
cluding the records of tomato juice consumption.
The participants’ menopausal symptoms were evalu-
ated using MSS, Hospital Anxiety and Depression Scale
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after 4 and 8 weeks of study participation. At each time
point, body composition, blood pressure, heart rate, and
REE, as well as serum levels of TG, total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, and plasma levels of glu-
cose and hemoglobin A1c (HbA1c) were measured.
The MSS was validated and used in previous studies
for participants to rate the severity of ten menopausal
symptoms [21]. We evaluated vasomotor symptoms (hot
flashes, perspiration, and chilliness); somatic symptoms
(irregular heartbeat, headache/dizziness, tiredness, and
aching joints/muscles); and psychological symptoms (in-
somnia, irritability, and depressed mood) using a 4-point
Likert scale, depending on how often each symptom af-
fected their daily life: none (never, 0 points); mild (rarely,
1 point); moderate (sometimes, 2 points); severe (very
often, 3 points). MSS scores were calculated as the total
score for the 10 aforementioned symptoms.
Developed by Zigmond and Snaith as a questionnaire
[22], the HADS is a reliable instrument for screening
clinically significant anxiety and depression in women;
the questionnaire was translated into Japanese by Kita-
mura et al. [23]. The AIS was developed as a brief, easy-
to-administer self-assessment questionnaire for deter-
mining insomnia severity according to the International
Classification of Disease, Tenth Revision. The internal
consistency and test-retest reliability of the AIS was pre-
viously confirmed [24]. The current study followed
the protocol reported earlier [25], who measured the ef-
fect of supplementation with grape seed proanthocyani-
din extracts on determining insomnia severity using
AIS [24] and screening of clinically significant anxiety
and depression using the Japanese version of HADS
questionnaire [23].
The body composition of the participants, including
height, weight, body mass index, fat mass, and muscle
mass, was assessed using a body composition analyzer
(MC190-EM; Tanita, Tokyo, Japan). Participants’ systolic
and diastolic blood pressure and heart rate were also mea-
sured using a vascular screening system (VS-1000; Fukuda
Denshi, Tokyo, Japan). Additionally, REE was measured
using a portable, indirect calorimeter (Metavine-N VMB-
005 N; Vine, Tokyo, Japan).
Blood samples were collected by antecubital venipuncture
and were centrifuged for the collection of serum. The
serum and plasma samples were sent within 3 days of
sampling to SRL, Inc. (Tokyo, Japan). The levels of serum
lipids, plasma glucose, and HbA1c were assayed according
to standard techniques.
Statistical analyses were performed using GraphPad
Prism version 5.02 (GraphPad Software, San Diego, CA,
USA) and IBM SPSS Statistics version 20 (IBM Corporation,
Armonk, NY, USA). After testing the normality of eachvaluable using Shapiro-Wilk test, the variables with
Gaussian distribution were evaluated with parametric
tests (One-way repeated measures ANOVA and paired
t-test) and those without were with non-parametric
tests (Friedman and Wilcoxon signed-rank tests). One-
way ANOVA and Kruskal-Wallis test were used for the
evaluations of baseline characteristics among four differ-
ent menopausal status groups and postprandial time for
blood sampling. P-values < 0.05 were considered statisti-
cally significant.
Results
Table 2 presents the characteristics at baseline and at 4
and 8 weeks after study commencement of the ninety-
three women (98%), who completed the 10-week study.
41 women (44%) were premenopausal, whereas 17 (18%)
were perimenopausal, 28 (30%) were postmenopausal,
and 7 (8%) had surgically or medically induced meno-
pause. Comparing the baseline data among the four
different menopausal status groups, we observed no
statistically significant differences except for serum levels
of total cholesterol (premenopausal, 197.8 ± 31.2 mg/dL;
perimenopausal, 231.9 ± 25.3 mg/dL; postmenopausal,
223.3 ± 31.1 mg/dL; had surgically or medically induced
menopause, 216.3 ± 40.3 mg/dL; P = 0.0005, One-way
ANOVA). The mean interval between the blood
sampling time and the previous meal at the 0-, 4-, and
8-week measurements were: 3.8 ± 2.2 hours, 4.1 ±
2.6 hours, and 4.2 ± 2.5 hours, respectively (P = 0.62,
Kruskal-Wallis test).
We evaluated the changes in menopausal symptom se-
verity using 3 scales. The mean MSS score (9.9 ± 5.2, at
baseline; mean ± standard deviation) was significantly im-
proved after 4 (8.5 ± 5.0, P = 0.0012, paired t-test) and 8
(8.3 ± 5.0, P < 0.0001) weeks of tomato juice consumption.
The mean HADS-anxiety subscale score also improved,
relative to baseline (5.3 ± 2.7) after 4 (4.8 ± 2.4,
P = 0.0170, Wilcoxon signed rank test) and 8 (4.9 ± 2.9,
P = 0.0337) weeks. There were no significant changes in
the mean HADS-depression subscale and AIS scores after
4 and 8 weeks of the intervention.
We also evaluated the changes in participant body
compositions, blood pressure, heart rate, and REEs. The
participant body composition parameters and blood
pressures did not change significantly after 4 and 8 weeks
of intervention. However, the mean heart rate was sig-
nificantly increased, compared to baseline (62.6 ±
9.4 bpm), after 4 (64.4 ± 8.6 bpm, P = 0.0046, Wilcoxon
signed rank test) and 8 (63.8 ± 8.2 bpm, P = 0.0020)
weeks of the intervention. In addition, the mean REE in-
creased after 4 (2108 ± 440 kcal/day, P = 0.0082, paired
t-test) and 8 (2149 ± 470 kcal/day, P = 0.0018) weeks of
tomato juice consumption, relative to baseline (1980 ±
368 kcal/day).
Table 2 Participant characteristics at baseline and at 4 and 8 weeks after study commencement
Baseline 4 weeks 8 weeks P-value
Menopausal symptom score
MSS score 9.9 (5.2) 8.5 (5.0)** 8.3 (5.0)*** <0.0001a
HADS-anxiety subscale score 5.3 (2.7) 4.8 (2.4)# 4.9 (2.9)# 0.04b
HADS-depression subscale score 4.7 (3.2) 4.6 (3.4) 4.4 (3.3) 0.32b
Athens Insomnia Scale score 3.7 (2.3) 3.4 (2.4) 3.8 (2.8) 0.16b
Body composition
Height, cm 157.5 (4.9) 157.5 (4.9) 157.5 (4.9) 0.50b
Weight, kg 55.0 (8.5) 54.9 (8.6) 55.0 (8.6) 0.13a
Body mass index, kg/m2 22.2 (3.2) 22.1 (3.2) 22.2 (3.2) 0.34a
Fat mass, kg 15.7 (6.1) 15.8 (6.2) 15.7 (6.2) 0.58b
Muscle mass, kg 37.0 (3.1) 36.9 (3.0) 37.1 (3.0) 0.046a
Blood pressure and heart rate
Systolic blood pressure, mmHg 116.9 (14.1) 117.8 (14.3) 117.0 (13.8) 0.87b
Diastolic blood pressure, mmHg 75.4 (10.4) 75.2 (9.7) 74.5 (9.3) 0.23b
Heart rate, min−1 62.6 (9.4) 64.4 (8.6)## 63.8 (8.2)## 0.03b
Resting Energy Expenditure 1980 (368) 2108 (440)** 2149 (470)** 0.003a
Blood examination
Triglycerides, mg/dL 115.9 (84.0) 116.3 (70.2) 107.4 (75.3) 0.25b
Total cholesterol, mg/dL 213.1 (33.4) 213.9 (36.1) 212.2 (36.8) 0.76a
LDL cholesterol, mg/dL 120.3 (28.8) 121.1 (31.2) 120.2 (32.2) 0.87a
HDL cholesterol, mg/dL 73.2 (16.3) 75.3 (14.9) 74.6 (15.0) 0.31a
Glucose, mg/dL 98.9 (16.6) 98.8 (11.6) 99.2 (19.0) 0.51b
HbA1c, % 5.3 (0.4) 5.3 (0.4) 5.4 (0.4) 0.36b
Data are shown as means (standard deviations).
aOne-way repeated measures analysis of variance.
bFriedman test.
**P < 0.01, ***P < 0.001 versus baseline, Paired t-test.
#P < 0.05, ##P < 0.01 versus baseline, Wilcoxon signed-rank test.
Figure 1 Change in serum TG level in the subgroup of women
who had hypertriglyceridemia at baseline (≥150 mg/dL). Data
are presented as means and standard errors. **P < 0.01, ***P < 0.001
versus baseline, Wilcoxon signed-rank test.
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and glucose. Although the serum TG level among all par-
ticipants did not change significantly, in the subgroup of
women (n = 22) with high TG levels at baseline (150 mg/dL
or higher; actual, 237.8 ± 88.9 mg/dL), the level de-
creased significantly after 4 (166.7 ± 86.1 mg/dL, P = 0.0002,
Wilcoxon signed rank test) and 8 (170.9 ± 109.7 mg/dL,
P= 0.0025) weeks of intervention (Figure 1). The serum
levels of total cholesterol, LDL cholesterol, HDL cholesterol,
glucose, and HbA1c did not change significantly.
Discussion
This open-label, single-arm study investigated the net ef-
fect of tomato juice intake on a variety of health parame-
ters in middle-aged women. The results indicated that
tomato juice intake alleviated some menopausal symp-
toms, including anxiety; increased REE and heart rate;
and lowered serum TG levels (in women with elevated
baseline levels).
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outcomes of this study should be summed effects of
them. Most of the clinical studies on the effects of toma-
toes, tomato juice, and tomato products have focused on
lycopene, a bioactive ingredient that is abundant in to-
matoes. Dietary intake of fresh tomatoes or tomato juice
is known to increase the serum lycopene level [26].
Lycopene is expected to reduce cardiovascular diseases,
osteoporosis, and mental disorders through its anti-
oxidative effects [10-14]. In 2012, Kim et al. isolated
13-oxo-ODA from tomato juice. They showed that
this juice component acted as a potent peroxisome
proliferator-activated receptor-alpha (PPARα) activator
to lower plasma and hepatic TG levels in an animal
model of obesity [15]. Further, in 2010, Nohara et al.
demonstrated that esculeoside A, a tomato saponin, re-
duced serum levels of TG and cholesterol, and amelio-
rated atherosclerotic lesions in ApoE-deficient mice [16].
Human studies have not been published, to our know-
ledge. We believe that the current study is the first to in-
vestigate the net effects of tomatoes or tomato products
on the health parameters, including menopausal symp-
toms, body composition, blood pressure, heart rate, and
serum levels of lipids and glucose, of middle-aged women.
In our study, menopausal symptoms improved following
regular consumption of tomato juice over a prolonged
(8-week) period. Although the mechanisms causing the
vasomotor symptoms that affect middle-aged women are
not yet fully understood, oxidative stress could be one of
the responsible factors [27]. Psychological symptoms are
likewise prevalent around menopause, and may be associ-
ated with oxidative stress [28]. The improvements in
menopausal symptoms observed in our study participants
could partly be explained by the anti-oxidative effect of
lycopene. A meta-analysis of 13 clinical trials [12] showed
that the least effective amount of lycopene to reduce
oxidative stress was 10 mg/day, much lower than the esti-
mated dosage in the current study, 44 mg/day. Further-
more, GABA, much more abundant in tomatoes than in
other vegetables and fruits [29], could be another candi-
date as its analog, gabapentin, has been proven to relieve
hot flush [30].
Our study also revealed that tomato juice intake in-
creased REE and heart rate, and, in women with elevated
baseline TG levels, lowered serum TG levels. 13-oxo-
ODA is a newly identified PPARα activator, first reported
in 2012 [15]. In their study, Kim et al. showed that
mouse rectal temperatures were significantly higher in
13-oxo-ODA-treated animals than in the controls, im-
plying that 13-oxo-ODA increased energy metabolism.
Their study also showed that plasma, liver, and skeletal
muscle TG levels were lower in the mice treated
with 47.6 mg/kg of 13-oxo-ODA than controls. On the
other hand, Nohara et al. focused on a tomato saponin,esculeoside A [16]. They showed that administration of
100 mg/kg/day of esculeoside A inhibited the accumula-
tion of cholesterol esters in macrophages, and reduced
serum levels of TG and cholesterol in ApoE-deficient
mice. The increase in energy metabolism and the de-
crease in serum TG level shown in our study could
be attributable to these bioactive ingredients, although
caution should be taken as the estimated dosage of
13-oxo-ODA in the current study, ~1.4 μg/kg, is far
smaller than that in the animal study, and we do not
know the exact amount of esculeoside A contained in
the tomato juice used. Further human studies investigat-
ing the effects of 13-oxo-ODA and esculeoside A on en-
ergy metabolism are warranted. The increase in heart
rate observed in the current study may be associated
with raised REE, as it is well known that heart rate is
linearly related to basal energy expenditure [31].
The present study has some limitations. First, it is de-
signed as a single-arm study because an adequate pla-
cebo or active control for tomato juice is difficult to
prepare. Second, blood samples should rather have been
collected in fasting status, which were unfortunately not
acceptable for many participants in our study. However,
the fact that the average postprandial intervals were not
significantly different among the groups would justify
the comparison between them. Third, some women may
have changed their eating and exercise habits during the
course of the 10-week study, although we requested
them to adhere to their current lifestyles. Finally, we
should rather have evaluated insulin resistance by meas-
uring plasma insulin concentration instead of HbA1c in
our relatively healthy participants.Conclusions
Tomato juice intake alleviated menopausal symptoms, in-
cluding anxiety, increased REEs and heart rate, and lowered
high baseline serum TG levels in middle-aged women.
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